James Faucette

Morgan Stanley | Technology

James Faucette is an analyst from Morgan Stanley specializing in the Technology sector. Ranked #2366 out of 4558 analysts, they have issued 80 stock ratings with a success rate of 75.97% and an average return of 6.46%.

James Faucette has a well-established track record, with 80 ratings issued in the Technology sector. They have consistently delivered a success rate of 75.97% and an average return of 6.46%, underscoring their expertise and ability to identify winning opportunities for investors.

#2366

Out of 4558

80

Total Ratings

+75.97%

Success Rate

+6.46%

Average Return

Recent Ratings Analysis

XYZ

Feb 27, 2026

Target

$93.00

Current

$63.70

Performance

0.00%

James Faucette rated XYZ as Overweight on Feb 27, 2026, setting a price target of 93. Shares have remained stable near 63.7, leaving the 93 target still in play.

VRRM

Feb 25, 2026

Target

$24.00

Current

$16.71

Performance

3.28%

On Feb 25, 2026, VRRM was given a Equal-Weight rating by James Faucette, with a target price of 24. Market indecision, reflected in sideways trading near 16.71, supported the cautious call.

MQ

Feb 25, 2026

Target

$6.00

Current

$3.84

Performance

-0.52%

MQ received a Equal-Weight rating from James Faucette on Feb 25, 2026, aiming for 6. Shares remained flat at 3.84, aligning with the neutral rating.

FLYW

Feb 24, 2026

Target

$16.00

Current

$12.31

Performance

9.52%

On Feb 24, 2026, James Faucette published a Equal-Weight outlook on FLYW, with a target of 16. The Hold call missed some of the bullish momentum as shares advanced toward 16.

KLAR

Feb 18, 2026

Target

$39.00

Current

$13.56

Performance

-28.44%

James Faucette on Feb 18, 2026 assigned KLAR a Equal-Weight rating, with a price target of 39. The call successfully avoided chasing as shares lost 28.44%.

IIIV

Feb 10, 2026

Target

$28.00

Current

$22.38

Performance

-3.07%

On Feb 10, 2026, James Faucette reaffirmed IIIV with a Equal-Weight rating, targeting 28. The neutral call matched muted market action of -3.07%.

CTSH

Feb 05, 2026

Target

$82.00

Current

$64.43

Performance

-16.15%

CTSH was rated Equal-Weight by James Faucette on Feb 05, 2026, with a price objective of 82. Investors who stayed cautious avoided some of the 16.15% decline.

JKHY

Feb 05, 2026

Target

$183.00

Current

$162.46

Performance

-8.19%

On Feb 05, 2026, James Faucette initiated coverage on JKHY with a Equal-Weight rating and target of 183. The rating matched the stock’s inability to hold above 162.46.

CPAY

Feb 05, 2026

Target

$390.00

Current

$325.10

Performance

-2.96%

James Faucette issued a Overweight recommendation for CPAY on Feb 05, 2026, price target set at 390. The target of 390 remains in play, though confirmation will depend on future moves.

PYPL

Feb 04, 2026

Target

$34.00

Current

$46.21

Performance

12.62%

On Feb 04, 2026, PYPL was evaluated by James Faucette, who gave a Underweight rating and target of 34. Investors benefited from heeding the Sell stance, avoiding a 12.62% decline.

GLXY

Feb 04, 2026

Target

$36.00

Current

$20.59

Performance

2.13%

James Faucette rated GLXY as Overweight on Feb 04, 2026, setting a price target of 36. Shares have remained stable near 20.59, leaving the 36 target still in play.

AFRM

Feb 03, 2026

Target

$76.00

Current

$46.98

Performance

-23.81%

On Feb 03, 2026, AFRM was given a Overweight rating by James Faucette, with a target price of 76. Despite the Buy call, shares fell from 46.98 to 46.98, challenging the optimistic stance.

CRCL

Feb 02, 2026

Target

$66.00

Current

$83.44

Performance

41.76%

CRCL received a Equal-Weight rating from James Faucette on Feb 02, 2026, aiming for 66. Investors saw gains of 41.76% that the cautious stance didn’t fully capture.

MA

Jan 30, 2026

Target

$678.00

Current

$517.21

Performance

-4.01%

On Jan 30, 2026, James Faucette published a Overweight outlook on MA, with a target of 678. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 517.21.

V

Jan 30, 2026

Target

$411.00

Current

$320.14

Performance

-0.53%

James Faucette on Jan 30, 2026 assigned V a Overweight rating, with a price target of 411. The recommendation remains pending validation as shares consolidate around 320.14.

ADP

Jan 29, 2026

Target

$274.00

Current

$214.36

Performance

-12.85%

On Jan 29, 2026, James Faucette reaffirmed ADP with a Equal-Weight rating, targeting 274. The Hold stance reflected market caution that was later justified.

CWAN

Jan 27, 2026

Target

$24.55

Current

$23.39

Performance

-3.07%

CWAN was rated Equal-Weight by James Faucette on Jan 27, 2026, with a price objective of 24.55. Flat performance suggests the Hold view was reasonable.

PAYX

Dec 22, 2025

Target

$133.00

Current

$93.65

Performance

-18.48%

On Dec 22, 2025, James Faucette initiated coverage on PAYX with a Equal-Weight rating and target of 133. The rating matched the stock’s inability to hold above 93.65.

ACN

Dec 16, 2025

Target

$320.00

Current

$208.72

Performance

-23.28%

James Faucette issued a Overweight recommendation for ACN on Dec 16, 2025, price target set at 320. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

DAVA

Nov 13, 2025

Target

$8.00

Current

$4.68

Performance

-32.27%

On Nov 13, 2025, DAVA was evaluated by James Faucette, who gave a Equal-Weight rating and target of 8. The Hold call avoided chasing into subsequent weakness of 32.27%.

EVTC

Nov 12, 2025

Target

$29.00

Current

$28.31

Performance

-2.98%

James Faucette rated EVTC as Equal-Weight on Nov 12, 2025, setting a price target of 29. The Hold stance appears justified, as shares hovered around 28.31 with a -2.98% move.

RPAY

Nov 12, 2025

Target

$4.00

Current

$2.78

Performance

-22.99%

On Nov 12, 2025, RPAY was given a Equal-Weight rating by James Faucette, with a target price of 4. The rating provided protection from downside risk as the stock fell to 2.78.

NRDS

Nov 10, 2025

Target

$14.00

Current

$10.85

Performance

-24.39%

NRDS received a Equal-Weight rating from James Faucette on Nov 10, 2025, aiming for 14. The Hold stance proved prudent, with the market softening by 24.39%.

BR

Nov 05, 2025

Target

$256.00

Current

$185.87

Performance

-14.96%

On Nov 05, 2025, James Faucette published a Equal-Weight outlook on BR, with a target of 256. Weakness in the stock, now at 185.87, supported the conservative rating.

SSNC

Oct 24, 2025

Target

$92.00

Current

$75.29

Performance

-11.04%

James Faucette on Oct 24, 2025 assigned SSNC a Equal-Weight rating, with a price target of 92. The call successfully avoided chasing as shares lost 11.04%.

FOUR

Oct 03, 2025

Target

$86.00

Current

$44.07

Performance

-42.66%

On Oct 03, 2025, James Faucette reaffirmed FOUR with a Equal-Weight rating, targeting 86. The Hold stance reflected market caution that was later justified.

UWMC

Sep 29, 2025

Target

$6.50

Current

$4.41

Performance

-29.10%

UWMC was rated Equal-Weight by James Faucette on Sep 29, 2025, with a price objective of 6.5. Investors who stayed cautious avoided some of the 29.10% decline.

KD

Sep 26, 2025

Target

$30.00

Current

$12.33

Performance

-58.13%

On Sep 26, 2025, James Faucette initiated coverage on KD with a Equal-Weight rating and target of 30. The rating matched the stock’s inability to hold above 12.33.

NCNO

Sep 10, 2025

Target

$36.00

Current

$16.14

Performance

-46.16%

James Faucette issued a Overweight recommendation for NCNO on Sep 10, 2025, price target set at 36. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

EPAM

Sep 09, 2025

Target

$175.00

Current

$141.00

Performance

-14.56%

On Sep 09, 2025, EPAM was evaluated by James Faucette, who gave a Equal-Weight rating and target of 175. The Hold call avoided chasing into subsequent weakness of 14.56%.

TASK

Sep 09, 2025

Target

$16.50

Current

$10.62

Performance

-39.52%

James Faucette rated TASK as Equal-Weight on Sep 09, 2025, setting a price target of 16.5. The cautious Hold call aligned with subsequent weakness, as shares slipped 39.52%.

UPST

Aug 06, 2025

Target

$70.00

Current

$27.23

Performance

-59.44%

On Aug 06, 2025, UPST was given a Equal-Weight rating by James Faucette, with a target price of 70. The rating provided protection from downside risk as the stock fell to 27.23.

TIXT

Aug 04, 2025

Target

$3.40

Current

$4.31

Performance

15.24%

TIXT received a Equal-Weight rating from James Faucette on Aug 04, 2025, aiming for 3.4. Investors saw gains of 15.24% that the cautious stance didn’t fully capture.

DXC

Aug 01, 2025

Target

$15.00

Current

$12.59

Performance

-2.10%

On Aug 01, 2025, James Faucette published a Equal-Weight outlook on DXC, with a target of 15. Sideways action left the Hold view intact, with no major move since 12.59.

WU

Jul 29, 2025

Target

$7.00

Current

$9.63

Performance

19.04%

James Faucette on Jul 29, 2025 assigned WU a Underweight rating, with a price target of 7. The market validated the bearish call with a pullback to 9.63.

WEX

Jul 25, 2025

Target

$170.00

Current

$149.19

Performance

-15.05%

On Jul 25, 2025, James Faucette reaffirmed WEX with a Equal-Weight rating, targeting 170. The Hold stance reflected market caution that was later justified.

CHYM

Jul 07, 2025

Target

$39.00

Current

$22.13

Performance

-30.08%

CHYM was rated Overweight by James Faucette on Jul 07, 2025, with a price objective of 39. This case shows how bullish projections can fail, with the stock now below 22.13.

GLBE

Mar 26, 2025

Target

$46.00

Current

$34.97

Performance

-6.10%

On Mar 26, 2025, James Faucette initiated coverage on GLBE with a Overweight rating and target of 46. The Buy call has yet to be validated as shares remain 11.03 away from the target.

AVDX

Feb 27, 2025

Target

$8.00

Current

$10.00

Performance

35.87%

James Faucette issued a Equal-Weight recommendation for AVDX on Feb 27, 2025, price target set at 8. A neutral call gave way to stronger-than-expected performance, closing in on 8.

GPN

Feb 14, 2025

Target

$163.00

Current

$76.46

Performance

-27.62%

On Feb 14, 2025, GPN was evaluated by James Faucette, who gave a Overweight rating and target of 163. Investors saw limited payoff as shares fell short of the 163 target.

FIS

Feb 12, 2025

Target

$86.00

Current

$50.96

Performance

-29.79%

James Faucette rated FIS as Equal-Weight on Feb 12, 2025, setting a price target of 86. The cautious Hold call aligned with subsequent weakness, as shares slipped 29.79%.

RKT

Dec 19, 2024

Target

$13.00

Current

$18.19

Performance

56.41%

On Dec 19, 2024, RKT was given a Equal-Weight rating by James Faucette, with a target price of 13. The stock rallied from 18.19 to 18.19 after the Hold rating, surprising to the upside.

SQ

Dec 18, 2024

Target

$65.00

Current

$83.46

Performance

-4.40%

SQ received a Underweight rating from James Faucette on Dec 18, 2024, aiming for 65. Bearish momentum failed to push shares lower, as they hovered around 83.46.

QTWO

May 02, 2024

Target

$50.00

Current

$48.12

Performance

-19.23%

On May 02, 2024, James Faucette published a Equal-Weight outlook on QTWO, with a target of 50. Weakness in the stock, now at 48.12, supported the conservative rating.

Frequency Asked Questions

Who is James Faucette?

James Faucette is an analyst from Morgan Stanley specializing in the Technology sector.

What is James Faucette's success rate?

James Faucette currently has a success rate of +75.97%.

How many ratings has James Faucette issued?

James Faucette has issued 80 stock ratings so far.

What is the average return of James Faucette's calls?

Their stock ratings have generated an average return of +6.46%.

What is James Faucette's ranking?

James Faucette is ranked #2366 out of 4558 analysts.

What types of ratings does James Faucette give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow James Faucette?

You can follow James Faucette by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by James Faucette?

Their latest rating was a Buy on XYZ issued on 2026-02-27.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep